Equipment will allow you to quickly determine the presence or absence of pathogens of coronavirus disease<\/p>\n
March 23, 2020. \u2014 Biopharma<\/a>, which is one of the ten largest Ukrainian manufacturers of the pharmaceutical industry and specializes in human blood plasma drugs, has submitted to the laboratories of the Public Health Center of the Ministry of Health of Ukraine<\/a> equipment that will allow the presence and absence of samples to be determined quickly and by modern methods agents of coronavirus disease. This decision, in conjunction with entrepreneur Vasyl Khmelnytsky’s UFuture<\/a> holding company, is a continuation of a series of social initiatives undertaken by Ukrainian entrepreneurs amid a coronavirus pandemic.<\/p>\n “The Center will become the main reference site that will monitor the correctness of diagnostics throughout Ukraine. In other words, samples from laboratories will be sent here to confirm or refute the diagnosis. Without the transferred equipment, effective control of coronavirus disease in Ukraine would be defective,” Kostiantyn Yefymenko, President of Biopharma, reported.<\/cite><\/p><\/blockquote>\n The first unit is the Nuclear Acid Extraction Equipment from Thermo Fisher Scitific with consumables for 20,000 samples. The equipment helps prepare samples for analysis. The second unit is the equipment of Bio-Rad CFX 96 for molecular genetic analysis by PCR for the presence of a DNA virus and a system test for the detection of COVID-19.<\/p>\n The total cost of the equipment exceeds six million UAH, its installation and startup is performed by the company “ALT Ukraine LTD”. The equipment allows to process up to 100 samples in 60 minutes and in total about 2 thousand analyzes per day.<\/p>\n “Business should do everything in its power to stop the spread of the coronavirus and bring Ukraine back to normal. First of all, we need quality and timely diagnostics. already hundreds of millions of hryvnias and assistance continue,” Vasyl Khmelnytsky, founder of UFuture, said.<\/cite><\/p><\/blockquote>\n In addition, UFuture purchased two lung ventilation devices and all materials for their operation for the amount of 1 million 700 thousand UAH to one of the hospitals in Kyiv, and Biopharma \u2014 equipment for Bila Tserkva city hospital \u21163 (reference infectious hospital for the Kyiv region) with an amount of five million UAH.<\/p>\n Among them: The total cost of assistance from the holding companies is more than 12 million UAH. Also, masks and systems for rapid tests for the hospitals of Bila Tserkva will be purchased soon.<\/p>\n ADDITIONAL INFORMATION<\/strong><\/p>\n UFuture<\/strong><\/a> is a holding company of Ukrainian entrepreneur Vasyl Khmelnytsky that integrates his business and impact-investment projects. The company has a diversified portfolio of assets<\/a> in the fields of real estate, infrastructure, industry, renewable energy, pharmaceuticals, and IT. Currently, UFuture\u2019s assets are estimated at $550 million, and the total capitalization of the businesses it invested in is more than $1 billion.<\/p>\n
\n\u2022 two AR-203 artificial ventilation apparatus;
\n\u2022 AS-200 biochemical automatic analyzer;
\n\u2022 3-Part DiffH 18 light haematology analyzer;
\n\u2022 EasyStat blood gas and electrolyte analyzer;
\n\u2022 BM1600 patient monitor with BM200 module;
\n\u2022 Laura Smart urine analyzer;
\n\u2022 two microscopes Micromed Fusion FS-7620.<\/p>\n